about
S100B protein may detect brain death development after severe traumatic brain injury.Acute predictors for mortality after severe TBI in Spain: Gender differences and clinical data.Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.The utility of C-reactive protein and procalcitonin for sepsis diagnosis in critically burned patients: A preliminary studyThe effectiveness and safety of pharmacological prophylaxis against venous thromboembolism in patients with moderate to severe traumatic brain injury: A systematic review and meta-analysis.Multiple sclerosis and alcohol use disorders: In-hospital mortality, extended hospital stays, and overexpenditures.Serologic behavior of S100B protein in patients who are brain dead: preliminary results.Improving the appropriateness of antimicrobial use in primary care after implementation of a local antimicrobial guide in both levels of care.Severe Supratentorial Intracerebral Hemorrhage: Factors Related to Brain Death Development.Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.S100B and Neuron-Specific Enolase as mortality predictors in patients with severe traumatic brain injury.Role of L-type Ca(2+) channels, sarcoplasmic reticulum and Rho kinase in rat basilar artery contractile properties in a new model of subarachnoid hemorrhage.Point-of-care haemostasis monitoring during liver transplantation reduces transfusion requirements and improves patient outcome.Predictors of mortality and poor functional outcome in severe spontaneous intracerebral hemorrhage: a prospective observational study.Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.[An experimental model of mass-type brain damage in the rat: expression of brain damage based on neurospecific enolase and protein S100B].[Traumatic brain injury: severity assessment].[High mortality of meningococcal group C disease in adults in the Seville province, Spain (2008-2012)].Urotensinergic system genes in experimental subarachnoid hemorrhage.Effect of a single dose of lidocaine and ketamine on intraoperative opioids requirements in patients undergoing elective gynecological laparotomies under general anesthesia. A randomized, placebo controlled pilot study.Validation of S100B use in a cohort of Spanish patients with mild traumatic brain injury: a multicentre study.The Effect of Monthly Medication on Mortality After a Coronary Event.Serum brain injury biomarkers as predictors of mortality after severe aneurysmal subarachnoid hemorrhage: preliminary results.IMPACT Score for Traumatic Brain Injury: Validation of the Prognostic Tool in a Spanish Cohort.Role of S100B protein in urine and serum as an early predictor of mortality after severe traumatic brain injury in adults.Clinical variables and neuromonitoring information (intracranial pressure and brain tissue oxygenation) as predictors of brain-death development after severe traumatic brain injury.Accuracy of the S100β protein as a marker of brain damage in traumatic brain injury.Effect of freezing-thawing process on neuron specific enolase concentration in severe traumatic brain injury sera samples.Rapid and simplified synthesis of [18F]Fluoromisonidazole and its use in PET imaging in an experimental model of subarachnoid hemorrhage.Comparison of two competitive enzyme immunoassay kits for quantification of plasma Urotensin-II in rats.Prognostic value of total antioxidant capacity to predict functional outcome in traumatic brain injury patients.Short-term Results From a Training Program to Improve Organ Donation in Uncontrolled Donation After Circulatory Death.[Computed tomography as a tool to detect potential brain-dead donors].Serum gelsolin levels in aneurismal subarachnoid hemorrhage: Preliminary results.Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel diseaseLong-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data.[Survival in cardiopulmonary arrest according to the hospital area in which it is detected][Appropriateness of antibiotic prescribing in a primary care area: a cross-sectional study]Usefulness of optic nerve ultrasound to predict clinical progression in multiple sclerosisCold Ischemia Time as a Factor in Post-transplantation Complications for Orthotopic Hepatic Transplantation
P50
Q30428472-BE5531E0-C990-4DF5-815D-D93302ECC508Q30989636-43FB7335-823A-4128-8B94-4D0438E97D28Q33843746-92B5AC91-2A7C-4AF9-B0F9-5D85C302B3E7Q36331500-6B790579-8F5A-434D-A124-03ABDC5548F8Q38849065-ED66C3B7-4707-4BBD-9392-49780CCC7E38Q39250357-9208BFAB-CBD8-4BA8-BA55-EB06A2B2FE04Q39299739-FF9A31CA-7565-4D86-A58E-EADF1397ED17Q40197481-2607761D-B087-4EA5-A654-91FFC333A349Q40199059-F47C7606-D4E1-4222-865F-62046F393AE7Q40227111-E5A8CD4C-0F9A-4AE2-AB59-2755AD069318Q40800244-C23EFA62-8B5C-4A78-A639-3510BF406506Q40982174-E4992ABB-8DD7-4E13-9B25-8A69C38E7B59Q41008890-612AA0A9-422A-44C5-8BCB-9A29441B2A15Q41699604-3CC64819-E298-47D1-BEA9-037CB730DF04Q42701889-843F3FB8-539B-493F-9C11-26A5BBAAB7CFQ43893492-F20D1B25-58F0-4744-BB40-449790B1CE76Q45764731-D82DD3C5-BC6D-4FCF-A8BB-29C0BAC456C9Q45908528-ADC231AA-A5F7-4046-92B0-9E82EDA1615AQ47587344-942CBA69-700A-4FC9-9FFE-3A8E9AD9E636Q47590082-6C61F2F6-3EAD-45F0-A342-DCD6850E72B6Q47848745-24FF09F8-E38A-4894-AD4A-B25D85145356Q48244402-D5BB764F-4654-4909-AF57-92EC7FF570FBQ48276399-04E7E9F5-A599-4AB4-AD25-5AEA2D500F89Q48309718-B7211EF0-A042-4BDF-82A2-3CC23308AF39Q48352516-D7E2182B-E56B-4FAF-95A3-6CE070F5A074Q48378585-CA50268B-0D3F-47BE-AE01-85291400BC29Q48794468-66F7264D-81C0-4472-8A48-5A50D1FDBA3EQ48858532-8222EB81-C22B-4EBB-8631-B03974AC2AE0Q49677826-363BF10C-DF61-4BE5-AADC-E1B8D1CF3D6AQ51110990-3D061EB1-F56D-4838-9460-96BA5DE350F7Q52098538-B474D3E6-3B82-4987-9495-43837B78FFC9Q52630618-6A0B8172-E518-47C8-84FB-FAD985D40DBAQ53037622-94A51E54-526D-4F5D-B15B-CD75C51E8BACQ54455362-466DD107-48EB-4538-A36E-5497B198D499Q60302346-C0BB640E-CB79-4288-8A69-CDBEBC8C5794Q64983137-0F238248-65E2-4F1C-8D7A-BE123CB826D8Q83089597-C76CC943-51D2-4058-8ED7-4CFAF3CF8A61Q87115114-9C7E6CD6-4FE9-4C32-9485-E8A64C1CC2A2Q88158491-CFFE4A71-C6D4-4E5F-B972-1F126F0073CDQ88177272-F4078062-F75E-4BB0-9990-4F930658DD7B
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
A Vilches-Arenas
@en
A Vilches-Arenas
@nl
type
label
A Vilches-Arenas
@en
A Vilches-Arenas
@nl
prefLabel
A Vilches-Arenas
@en
A Vilches-Arenas
@nl
P31
P496
0000-0003-2197-3760